Celgene strikes $100 million deal for option to buy cancer drug maker Acetylon

Celgene entered into a drug development collaboration paying $100 million for an option to buy its new partner, closely held Acetylon Pharmaceuticals, which is in the early stages of testing a therapy for multiple myeloma.